14 employees
Normunity develops precision immuno-oncology medicines that enable normal immunity against cancer.
2021
$65M
from 3 investors over 3 rounds
Normunity raised $65M on October 25, 2022
Investors: Sanofi Ventures, Osage University Partners (OUP) and Canaan